Company / R&D Expense
Celularity Inc R&D Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$15.0M
FY2025
5-year range
$15.0M / $88.4M
FY2021-FY2025
Trend
-13.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has declined for 4 consecutive years, from $88M in FY2021 to $15M in FY2025.
Based on SEC 10-K filings.
$15M in FY2025 with a 3-year CAGR of -42.3%.
Declined from $30M to $15M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -42.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Celularity Inc's r&d expense has declined for 4 consecutive years.
- 3-year CAGR of -42.3%, indicating a declining trend.
- In FY2025, r&d expense decreased 13.6% year-over-year.
- Peak r&d expense was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $15.0M | -13.6% |
| FY2024 | $17.4M | -42.9% |
| FY2023 | $30.5M | -61.1% |
| FY2022 | $78.4M | -11.3% |
| FY2021 | $88.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 29, 2026